Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
3.1 Roche / Zealand (Petrelintide Amylin Analog) Deal: On March 12, 2025, Roche licensed petrelintide (CT-388) from Denmarks Zealand Pharma for obesity
It is commonly paired with Ipamorelin, a synthetic peptide studied in laboratory models for its selective interaction with growth hormonerelated signaling pathways
FDA Approvals: Semaglutide: Approved for both type 2 diabetes (Ozempic) and weight loss (Wegovy)
Tirzepatide can suppress appetite so effectively that some people eat 500-800 calories daily without realizing it
This discovery could lead to more targeted obesity treatments that preserve the benefits of GLP-1R agonists while minimizing discomfort
For people who meet clinical BMI criteria, have tried sustained diet and exercise without lasting results, and lack insurance coverage for FDA-approved GLP-1s, Yucca Health's compounded options may represent a financially accessible path to medications that clinical evidence suggests can support meaningful weight loss alongside lifestyle changes
